This study wanted to find out if two medications, gabapentin (Neurontin) and pregabalin (Lyrica) helped relieve symptoms of hot flushes and night sweats in postmenopausal women and women with breast cancer receiving hormonal therapy. The study found that gabapentin reduced the frequency of hot flushes in these women.

This review aimed to summarize available data about the effectiveness of mindfulness-based interventions for cancer-related symptoms in cancer patients and survivors.  

This review concluded that mindfulness-based interventions can have a beneficial effect as an adjuvant therapy in these patients.  

This study wanted to find out which treatment resulted in better overall survival for patients with HER2+ breast cancer; trastuzumab emtansine (Kadcycla) with or without pertuzumab (Perjeta), or trastuzumab (Herceptin) plus a taxane. The study found that the overall survival was similar across all groups. 

This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission.  

This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete remission.  

The study aimed to investigate if home-based physical activity was effective in improving the symptoms of patients with breast cancer who were receiving primary treatment.  

This study concluded that home-based physical activity is effective in improving some outcomes for these patients.  

This study investigated if a combination including pertuzumab (Perjeta) and subcutaneous trastuzumab (Herceptin Hylecta) is safe in breast cancer (BC). 

They found that this combination was well tolerated in patients with HER2-positive BC.

This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment.

This study investigated the effectiveness and side effects on the heart of anthracycline-based therapies (ABTs) for breast cancer. They found that non-doxorubicin (non-DXR) ABTs had a better benefit/risk ratio (BRR) than DXR alone. 

This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States.

This study wanted to find out if lisinopril (Zestril) or carvedilol (Coreg) can help prevent heart problems in patients with HER2 positive breast cancer who are treated with trastuzumab (Herceptin). The study found that both of these medications helped reduce the chance of heart problems in these patients if they were also being treated with anthracyclines.